GlassScriptPhysician profile
Joseph Negusei
NPI 1285077065
$6,391.18
in general payments reported to CMS, 2019-2025
31 companies · $1,280 in 2025
The $1,280 reported for 2025 was more than what 75% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $64.75 · 2021: $293 · 2022: $565 · 2023: $1,762 · 2024: $2,426 · 2025: $1,280.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,079 · Travel and Lodging: $1,389.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,079.27 |
| Travel and Lodging | $1,388.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $1,723.09 | 2023-2024 | Mitraclip, Gallant, Cardiomems |
| Amgen INC. | $703.51 | 2020-2025 | Repatha, Repatha |
| Novartis Pharmaceuticals Corporation | $693.81 | 2023-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $539.02 | 2020-2025 | Jardiance |
| Merck Sharp & Dohme LLC | $447.06 | 2021-2025 | Verquvo |
| Pfizer INC. | $298.41 | 2020-2025 | |
| E.R. Squibb & Sons, L.L.C. | $292.20 | 2021-2025 | Camzyos, Eliquis |
| Astrazeneca Pharmaceuticals LP | $283.19 | 2021-2025 | Farxiga, Lynparza |
| Alnylam Pharmaceuticals INC. | $222.40 | 2023-2025 | Onpattro |
| Novo Nordisk INC | $190.17 | 2023-2025 | Wegovy, Ozempic, Rybelsus |
| Cvrx, INC. | $145.13 | 2023 | Barostim Neo System |
| Esperion Therapeutics, INC. | $117.77 | 2021-2025 | Nexletol |
| Sanofi-Aventis U.S. LLC | $101.80 | 2022-2023 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $86.92 | 2023-2025 | Lifevest |
| Boston Scientific Corporation | $72.09 | 2023-2024 | Watchman Flx, Watchman Access System |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $66.87 | 2025 | |
| Lantheus Medical Imaging, INC. | $51.08 | 2021-2023 | Definity |
| Lexicon Pharmaceuticals, INC. | $48.57 | 2023-2024 | Inpefa |
| Abiomed | $38.69 | 2025 | |
| Janssen Pharmaceuticals, INC | $37.75 | 2024 | Xarelto |
| Bridgebio Pharma, INC. | $34.20 | 2025 | Attruby |
| Kiniksa Pharmaceuticals, LTD. | $31.13 | 2022-2023 | Arcalyst |
| Scpharmaceuticals INC. | $27.43 | 2024 | |
| Kowa Pharmaceuticals America, INC. | $27.33 | 2021 | |
| Cleerly, INC. | $23.96 | 2024 | Cleerly Labs, Cleerly Ischemia |
| Ionis Pharmaceuticals, INC. | $16.64 | 2025 | Tryngolza |
| Heartflow, INC. | $15.17 | 2025 | |
| Amarin Pharma, INC. | $14.78 | 2023 | |
| Lilly USA, LLC | $14.32 | 2025 | Zepbound, Mounjaro |
| Horizon Therapeutics Plc | $13.35 | 2023 | Krystexxa |
| Arbor Pharmaceuticals, INC. | $13.34 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Negusei listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.